Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p509-509, 151p
- Subject
- Language
- ISSN
- 0732183X